Ingersoll Rand
IR
77.24
-1.97
-2.49%
Ingersoll Rand
US · IR
#696 by market cap
Listed 1970
77.24
-1.97
-2.49%
Live - 5344 symbols - heartbeat 189s ago
· 2026-10-08 04:05
Pre-market
77.00
-0.31%
After-hours
77.24
0.00%
Overnight
77.00
-0.31%
- Market cap
- 29.97B
- P/E (TTM)i
- 31.92
- P/Bi
- 2.94
- EPSi
- 1.45
- Div yieldi
- 0.10%
- 52W posi
- 28%
Reader sentiment
Are you bullish or bearish on IR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.28, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +5.75% YoY
Margins
- Gross margin
- 43.61%
- Operating margin
- 19.74%
- Net margin
- 7.60%
Key ratios & quality
- Enterprise valuei
- 33.57B
- Altman Z-Scorei
- 3.28
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.69B | 2.02B | 3.97B | 5.15B | 5.92B | 6.88B | 7.24B | 7.65B |
| Gross profit | 1.01B | 778.30M | 1.40B | 1.99B | 2.33B | 2.88B | 3.17B | 3.34B |
| Selling & admin expenses | 434.60M | 409.60M | 789.30M | 1.03B | 1.10B | 1.27B | 1.34B | 1.44B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 453.00M | 260.30M | 274.40M | 622.40M | 879.40M | 1.24B | 1.45B | 1.51B |
| Pretax profit | 349.50M | 110.20M | -45.40M | 513.00M | 742.20M | 1.03B | 1.13B | 935.30M |
| Tax | 80.10M | 12.90M | 11.40M | -21.80M | 149.60M | 240.00M | 262.50M | 219.40M |
| Net profit | 269.40M | 159.10M | -32.40M | 565.00M | 608.50M | 785.10M | 846.30M | 588.80M |
| Basic EPS | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 |
| Diluted EPS | 1.29 | 0.76 | -0.09 | 1.34 | 1.47 | 1.90 | 2.06 | 1.45 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.72B | 1.89B | 1.96B | 2.09B | 1.85B | 2.05B |
| Gross profit | 765.50M | 824.90M | 855.20M | 890.70M | 792.40M | 862.60M |
| Selling & admin expenses | 350.00M | 371.20M | 361.00M | 357.10M | 370.70M | 400.80M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 324.40M | 363.20M | 398.50M | 423.90M | 314.20M | 358.50M |
| Pretax profit | 253.10M | 28.10M | 319.40M | 334.70M | 229.90M | 327.10M |
| Tax | 58.50M | 21.00M | 73.60M | 66.30M | 36.10M | 69.10M |
| Net profit | 188.40M | -113.80M | 245.80M | 268.40M | 193.80M | 258.00M |
| Basic EPS | 0 | 0 | 1 | 1 | 0 | 1 |
| Diluted EPS | 0.46 | -0.29 | 0.61 | 0.67 | 0.49 | 0.66 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.33B | 1.54B | 3.86B | 4.11B | 3.97B | 4.05B | 4.16B | 4.25B |
| Cash & ST investments | 221.20M | 505.50M | 1.75B | 2.11B | 1.61B | 1.60B | 1.54B | 1.25B |
| Inventory | 523.90M | 502.50M | 716.70M | 854.20M | 1.03B | 1.00B | 1.06B | 1.17B |
| Total assets | 4.49B | 4.63B | 16.06B | 15.15B | 14.77B | 15.56B | 18.01B | 18.30B |
| Total current liabilities | 596.40M | 574.60M | 1.50B | 1.47B | 1.67B | 1.83B | 1.82B | 2.07B |
| Short-term debt | 7.90M | 24.70M | 87.50M | 73.70M | 76.10M | 72.20M | 59.40M | 66.20M |
| Long-term debt | 1.66B | 1.60B | 3.86B | 3.40B | 2.72B | 2.69B | 4.75B | 4.78B |
| Total liabilities | 2,811,100,000.00 | 2,758,500,000.00 | 6,869,100,000.00 | 6,083,300,000.00 | 5,508,700,000.00 | 5,716,800,000.00 | 7,764,500,000.00 | 8,143,200,000.00 |
| Total equity | 1.68B | 1.87B | 9.19B | 9.07B | 9.26B | 9.85B | 10.25B | 10.15B |
| Retained earnings | -308.70M | -141.40M | -175.70M | 378.60M | 950.90M | 1.70B | 2.50B | 3.05B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 4.35B | 4.19B | 4.16B | 4.25B | 4.29B | 4.29B |
| Cash & ST investments | 1.61B | 1.31B | 1.18B | 1.25B | 1.27B | 1.17B |
| Inventory | 1.13B | 1.21B | 1.26B | 1.17B | 1.24B | 1.23B |
| Total assets | 18.38B | 18.06B | 18.19B | 18.30B | 18.22B | 18.19B |
| Total current liabilities | 1.83B | 1.83B | 1.93B | 2.07B | 1.93B | 2.65B |
| Short-term debt | 64.00M | 65.40M | 65.60M | 66.20M | 66.20M | 764.10M |
| Long-term debt | 4.77B | 4.78B | 4.79B | 4.78B | 4.78B | 4.06B |
| Total liabilities | 7,825,700,000.00 | 7,901,700,000.00 | 8,000,500,000.00 | 8,143,200,000.00 | 7,978,400,000.00 | 7,951,100,000.00 |
| Total equity | 10.55B | 10.16B | 10.19B | 10.15B | 10.24B | 10.24B |
| Retained earnings | 2.68B | 2.56B | 2.79B | 3.05B | 3.24B | 3.49B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 444.50M | 343.30M | 914.30M | 615.50M | 860.30M | 1.38B | 1.40B | 1.36B |
| Depreciation & amortization | 180.40M | 146.50M | 412.50M | 422.10M | 432.80M | 459.10M | 482.00M | 505.80M |
| Free cash flow | 392.30M | 305.40M | 872.30M | 551.40M | 765.70M | 1.27B | 1.25B | 1.22B |
| Dividends paid | -- | 0 | 0 | -8.20M | -32.40M | -32.40M | -32.30M | -31.80M |
| Stock buybacks / issuance | -40.70M | -18.60M | -2.10M | -736.80M | -261.10M | -263.00M | -260.70M | -1.02B |
| Ending cash balance | 221.20M | 505.50M | 1.75B | 2.11B | 1.61B | 1.60B | 1.54B | 1.25B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 256.40M | 245.70M | 354.60M | 499.00M | 199.70M | 295.90M |
| Depreciation & amortization | 120.00M | 120.50M | 124.50M | 140.80M | 136.90M | 132.80M |
| Free cash flow | 222.70M | 210.40M | 325.50M | 461.50M | 163.40M | 268.90M |
| Dividends paid | -8.10M | -8.00M | -7.90M | -7.80M | -7.80M | -7.90M |
| Stock buybacks / issuance | -10.00M | -500.70M | -192.60M | -314.70M | -89.50M | -249.30M |
| Ending cash balance | 1.61B | 1.31B | 1.18B | 1.25B | 1.27B | 1.17B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 17.09 | 8.97 | -0.61 | 6.21 | 6.65 | 8.21 | 8.40 | 5.74 |
| ROA %i | 5.92 | 3.49 | -0.32 | 3.60 | 4.04 | 5.14 | 5.00 | 3.20 |
| ROIC %i | 10.09 | 6.81 | 0.58 | 4.90 | 5.62 | 7.33 | 7.28 | 5.18 |
| 5-year avg ROE %i | -- | -14.60 | 3.28 | 6.76 | 7.66 | 5.89 | 5.77 | 7.04 |
| EBIT margin %i | 16.70 | 11.41 | 1.87 | 11.66 | 14.29 | 17.27 | 18.60 | 15.54 |
| FCF / sales %i | 14.58 | 12.24 | 17.63 | 10.70 | 12.94 | 18.50 | 17.24 | 15.95 |
| Current ratioi | 2.23 | 2.69 | 2.58 | 2.80 | 2.37 | 2.22 | 2.29 | 2.06 |
| Quick ratioi | 1.25 | 1.68 | 1.74 | 2.08 | 1.63 | 1.55 | 1.58 | 1.34 |
| Debt / assetsi | 37.26 | 35.18 | 24.58 | 22.93 | 18.91 | 17.77 | 26.73 | 26.50 |
| LT debt / equityi | 99.30 | 85.77 | 42.32 | 37.79 | 29.54 | 27.53 | 46.71 | 47.41 |
| Interest coveragei | 4.51 | 3.15 | 0.83 | 6.85 | 8.19 | 7.58 | 6.31 | 4.68 |
| Revenue CAGR (3Y) %i | 8.14 | 1.32 | 18.70 | 24.19 | 43.13 | 20.06 | 11.98 | 8.95 |
| Net income CAGR (3Y) %i | -- | -- | -- | 27.81 | 56.06 | -- | 14.24 | -1.30 |
| FCF CAGR (3Y) %i | 57.14 | 49.61 | 82.42 | 12.02 | 35.85 | 13.40 | 31.28 | 16.80 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 8.09 | 5.21 | 5.35 | 5.74 | 5.68 | 9.47 |
| ROA %i | 4.85 | 2.91 | 3.00 | 3.20 | 3.21 | 5.29 |
| ROIC %i | 7.19 | 4.75 | 4.86 | 5.18 | 5.20 | 7.78 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 18.59 | 15.72 | 15.77 | 15.54 | 15.02 | 18.49 |
| FCF / sales %i | 18.83 | 17.63 | 16.75 | 15.95 | 14.92 | 15.35 |
| Current ratioi | 2.38 | 2.29 | 2.16 | 2.06 | 2.23 | 1.62 |
| Quick ratioi | 1.62 | 1.47 | 1.35 | 1.34 | 1.42 | 1.01 |
| Debt / assetsi | 26.30 | 26.84 | 26.68 | 26.50 | 26.59 | 26.56 |
| LT debt / equityi | 45.50 | 47.40 | 47.29 | 47.41 | 46.95 | 39.98 |
| Interest coveragei | 5.70 | 4.64 | 4.69 | 4.68 | 4.56 | 5.71 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Industrial Technologies and Services is the largest reported line at 79.17% of revenue, across 2 reported segments.
- The next-largest line, Precision and Science Technologies, is a distant second at 20.83% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Industrial Technologies and Services79.17%
Precision and Science Technologies20.83%
Quote time 2026-10-08 04:05:20 · For reference only, not investment advice and not tailored to your situation.